A real-world approach to CL care

Article

Compliance with contact lens care regimens in very low.

Key Points

Compliance with contact lens care regimens is very low-and, with a higher rate of lens-related complications among non-compliant wearers, the consequences of this are very real. (Cont Lens Anterior Eye. 2011; 34:216-222)

Teach compliance

To make compliance easier, we actually bundle solution and replacement cases with patients' contact lens orders. If they are following our instructions, they should run out of supplies at about the same time they need more contact lenses. I explain to patients that adherence to these guidelines will reduce their risk of infection and allow them to continue wearing contact lenses safely and comfortably.

Plan for noncompliance

Until recently, contact lens care products have been somewhat lacking in this regard. Multipurpose solutions (MPS) are easy to use, but the "no rub" wording on the packaging of some of these products may actively discourage rubbing, which I consider to be a key step not only in mechanical removal of deposits, but also in keeping patients engaged in their lens care. Most of our MPS products weren't tested on the most commonly prescribed lens materials, and disinfection efficacy was tested under laboratory conditions that are almost certainly not replicated by our patients on a day-to-day basis.

A new multipurpose disinfecting solution (MPDS), RevitaLens Ocutec (Abbott Medical Optics), addresses some of these problems. First, it has been designed and tested to be compatible with silicone hydrogel lenses. Considering that more than 50% (and growing) of my contact lens patients are now in silicone hydrogels, that's an important factor. It is labeled with a "rub and rinse" regimen that supports my clinical guidance to patients.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Setting the stage in LA: Neda Shamie, MD, on the 19th annual Controversies in Modern Eye Care meeting
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
© 2025 MJH Life Sciences

All rights reserved.